Łukasz Puslecki

Dr. Łukasz Puslecki

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in Emergency Medicine International
Verified
Journal Article
Open access
PDF file
MPMateusz Puslecki
Mateusz Puslecki
KBKonrad Baumgart
Konrad Baumgart
MLMarcin Ligowski
Marcin Ligowski
MDMarek Dabrowski
Marek Dabrowski
SSSebastian Stefaniak
Sebastian Stefaniak
BPBartlomiej Perek
Bartlomiej Perek
Background. Extracorporeal membrane oxygenation (ECMO) has been proven to support in lifesaving rescue therapy. The best outcomes can be achieved in high-volume ECMO centers with dedicated emergency transport teams. Aim. The aim of this study was to analyze the safety of ECMO support during medical transfer on the basis of our experience developed on innovation cooperation and review of literature. Methods. A retrospective analysis of our experience of all ECMO-supported patients transferred from regional hospital of the referential ECMO center between 2015 and 2020 was carried out. Special attention was paid to transportation-related mortality and morbidity. Moreover, a systematic review of the Medline, Embase, Cochrane, and Google Scholar databases was performed. It included the original papers published before the end of 2019. Results. Twelve (5 women and 7 men) critically ill ECMO-supported patients with the median age of 33 years (263 years) were transferred to our ECMO center. In 92 (n=11) of the cases venovenous and in 1 case, venoarterial supports were applied. The median transfer length was 45km (5200). There was no mortality during transfer and no serious adverse events occurred. Of note, the first ECMO-supported transfer had been proceeded by high-fidelity simulations. For our systematic review, 68 articles were found and 22 of them satisfied the search criteria. A total number of 2647 transfers were reported, mainly primary (90) and as ground transportations (91.6). A rate of adverse events ranged from 1 through 20 but notably only major complications were mentioned. The 4 deaths occurred during transport (mortality 0.15). Conclusions. Our experiences and literature review showed that transportation for ECMO patients done by experienced staff was associated with low mortality rate but life-threatening adverse events might occur. Translational simulation is an excellent probing technique to improve transportation safety.

30 November 2018 in Sustainability
Verified
Journal Article
Open access
PDF file
PTPiotr Trąpczyński
Piotr Trąpczyński
ŁPŁukasz Puslecki
Łukasz Puslecki
MSMichał Staszków
Michał Staszków
The involvement of firms in innovation cooperation with different partners has become a widespread phenomenon in the contemporary business landscape. Our paper provides a review of extant alliance, innovation, open innovation and inter-firm collaboration literature and organizes it based on a conceptual framework featuring three levels of analysis: (a) the dyadic level, (b) the network level, and (c) the location level. The article identifies roadmaps in each of these areas and also highlights existing gaps in the present understanding of innovation cooperation. Thereby, it outlines a research agenda by identifying key research questions and issues in the areas where further research is needed and encouraged.

26 October 2021
Verified
Book Chapter
Closed access
PDF file
ŁPŁukasz Puslecki
Łukasz Puslecki
MDMarek Dabrowski
Marek Dabrowski
CMCzekajlo Michael
Czekajlo Michael
PMPuślecki Mateusz
Puślecki Mateusz
The main aim of this chapter is to verify how innovation cooperation can support the improvement of patient care, taking into consideration new technological solutions – digital Health, medHealth, mobile health (mHealth), health information technology (IT), wearable devices, telehealth and telemedicine, and personalized medicine – and modern medical simulation. In addition, the authors present how such innovative cooperation should be developed in order to bring about appropriate results. The authors present examples of projects that use digital tools and artificial intelligence (AI) and which are focused on the delivery of new solutions to improve patient care. In order to deliver these solutions to the market faster, the role of innovation cooperation should not be forgotten. Taking this issue into account, the authors share the results of one of the first quantitative primary research projects in the world that focuses on innovation cooperation in the biopharmaceutical industry in the Central and Eastern Europe (CEE) region (covering 18 countries), as well as qualitative research: a focus group interview with representatives of the “ECMO (Extracorporeal Membrane Oxygenation) for Greater Poland” regarding the development of successful innovation cooperation as an example of translational innovation. Finally, the authors provide a translational innovation model that can be extrapolated to every industry, social, and economic area.

1 January 2023 in Entrepreneurial Business and Economics Review
Verified
Journal Article
Open access
ŁPŁukasz Puslecki
Łukasz Puslecki


22 June 2021
Verified
Book Chapter
Closed access
ŁPŁukasz Puslecki
Łukasz Puslecki
Purpose: This chapter seeks to verify the development of new partnerships and R&D alliances in the biopharmaceutical industry during the Covid-19 pandemic, but also to present the related challenges for innovation cooperation. Design/methodology/approach: The main method applied in this research was scientific study, meaning that the study applied descriptive, comparative, documentation, and desk research methods, along with deductive and inductive forecasting. Findings: The text presents new partnerships undertaken by biopharma companies (in and outside the industry) in order to face the pandemic and to discover and deliver anew vaccine for SARS-CoV-2 to the market. Moreover, the chapter describes the research projects in the European Union focused on the Covid-19 pandemic defeating. Thanks to more flexible and open cooperation, companies will greatly support the possibility to defeat the Covid-19 pandemic faster. Practical Implications: We should consider that due to the current situation caused by the Covid-19 pandemic, the cooperation of companies and all entities in the biopharmaceutical R&D innovation ecosystem is even more challenging than before. Moreover, we should remember that the organizational fluidity of open innovation initiatives and multiparty relations increases the complexity of alliance management. The use of an open innovation model can significantly hasten the production process of new drugs and vaccines. Originality and value: Biopharma-university alliances can significantly increase the likelihood of creating better medical therapies for patients. Results of such cooperation enable a number of innovative projects, given the significant pressure on innovativeness and challenges caused by the pandemic. Using the latest IT technologies will allow physicians to even better monitor, diagnose, and care for patients with afocus on the patient-centered approach.